ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Angela Lamarca,Daniel H. Palmer,Harpreet Wasan,Paul Ross,Yuk Ting Ma,Arvind Arora,Stephen Falk,Roopinder Gillmore,Jonathan Wadsley,K. Patel,Alan Anthoney,Anthony Maraveyas,Justin S. Waters,Claire Hobbs,Safia Barber,D. Ryder,John Ramage,Linda Davies,John Bridgewater,Juan W. Valle

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

2019

4003Background: Level A evidence supports use of CisGem as first-line chemotherapy for ABC; no robust evidence is available for second-line chemotherapy. Methods: Pts diagnosed with ABC with diseas...

Keywords:

Cisplatin/gemcitabine
Oncology
Oxaliplatin
Pathology
Biliary tract
Chemotherapy
Medicine
Internal medicine
locally advanced
open label study
multi centre
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

138

Citations